SANDOZ SERTRALINE 100 MG
SERTRALINE (SERTRALINE HYDROCHLORIDE) : 100 MG · DIN 02245161 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED POST MARKET
What is SANDOZ SERTRALINE?
SANDOZ SERTRALINE 100 MG contains SERTRALINE (SERTRALINE HYDROCHLORIDE) : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02245161, held by SANDOZ CANADA INCORPORATED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 05-Mar-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOZ SERTRALINE used for?
Symptomatic relief of depressive illness, panic disorder (with or without agoraphobia), and obsessive-compulsive disorder (OCD) in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02245161 |
|---|---|
| Brand name | SANDOZ SERTRALINE |
| Generic / active ingredient | SERTRALINE (SERTRALINE HYDROCHLORIDE) : 100 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 100 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AB06 SERTRALINE |
| AHFS class | 88:28.01* ; See footnote |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 05-Mar-2020 |
| Original market date | 2002-06-01 00:00:00 |
How is it administered?
Administer once daily with meals. Recommended starting dose for depression and OCD is 50 mg/day. For panic disorder, start at 25 mg/day, increasing to 50 mg/day after one week. Max dose 200 mg/day.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (standard practice is 15-30°C).
How is it supplied?
Not explicitly detailed in provided text (mentions bottles of 100 in general practice, but text only lists strengths).
Contraindications
Hypersensitivity to sertraline; concomitant use of MAOIs (including linezolid and methylene blue) or within 14 days of MAOI use; concomitant use of pimozide.
Warnings and precautions
Potential association with behavioural/emotional changes and suicidal ideation; risk of bone fracture; abnormal bleeding; QTc prolongation; Serotonin Syndrome; Seizures.
Is SERTRALINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AB06 SERTRALINE. 54 of 105 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-SERTRALINE | 100 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02477904 |
| AG-SERTRALINE | 25 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02477882 |
| AG-SERTRALINE | 50 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02477890 |
| APO-SERTRALINE | 100 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02238282 |
| APO-SERTRALINE | 25 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02238280 |
| APO-SERTRALINE | 50 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02238281 |
| AURO-SERTRALINE | 100 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02390922 |
| AURO-SERTRALINE | 25 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02390906 |
| AURO-SERTRALINE | 50 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02390914 |
| BIO-SERTRALINE | 100 MG | CAPSULE | BIOMED PHARMA | MARKETED | DIN 02445069 |
Who else supplies SERTRALINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SERTRALINE appears in 4790 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.